Main Street Research LLC Sells 8,516 Shares of Novo Nordisk A/S (NYSE:NVO)

Main Street Research LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 1.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 466,846 shares of the company's stock after selling 8,516 shares during the period. Novo Nordisk A/S makes up approximately 3.9% of Main Street Research LLC's investment portfolio, making the stock its 4th largest position. Main Street Research LLC's holdings in Novo Nordisk A/S were worth $48,295,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Pacific Center for Financial Services boosted its position in Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company's stock valued at $25,000 after buying an additional 135 shares during the period. Copeland Capital Management LLC boosted its position in Novo Nordisk A/S by 100.0% in the 3rd quarter. Copeland Capital Management LLC now owns 282 shares of the company's stock valued at $26,000 after buying an additional 141 shares during the period. Bell Investment Advisors Inc boosted its position in Novo Nordisk A/S by 79.9% in the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company's stock valued at $26,000 after buying an additional 127 shares during the period. Citizens National Bank Trust Department boosted its position in Novo Nordisk A/S by 100.0% in the 3rd quarter. Citizens National Bank Trust Department now owns 300 shares of the company's stock valued at $27,000 after buying an additional 150 shares during the period. Finally, Tyler Stone Wealth Management boosted its position in Novo Nordisk A/S by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company's stock valued at $27,000 after buying an additional 146 shares during the period. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 0.4 %

NYSE:NVO traded down $0.45 during midday trading on Tuesday, hitting $123.45. 3,043,212 shares of the company were exchanged, compared to its average volume of 4,933,779. The company has a fifty day simple moving average of $126.04 and a 200 day simple moving average of $110.09. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $553.99 billion, a PE ratio of 45.68, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The firm had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.33 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were given a dividend of $0.664 per share. This is an increase from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. This represents a yield of 0.9%. The ex-dividend date of this dividend was Friday, March 22nd. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 49.17%.

Analysts Set New Price Targets

Several equities analysts have commented on NVO shares. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an "overweight" rating and a $120.00 price target for the company. Cantor Fitzgerald restated an "overweight" rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Monday, April 1st. UBS Group began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a "neutral" rating on the stock. Finally, BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a report on Friday. They issued an "outperform" rating and a $163.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.